cropper
National Cannabis Newswire
  • Home
  • Categories
    • news
    • trends
    • insights
    • industry
    • legalization
    • health
    • culture
    • advocacy
    • Brands
    • New Mexico Dispensaries
    • Arizona Dispensaries
October 22.2026
3 Minutes Read

The Future of US Cannabis Contracts Hangs in the Balance—What You Need to Know

Fight Over US Cannabis Contract Enforcement Rights Could Come Back to Court

Unpacking the Legal Quagmire of Cannabis Contracts

The recent battle over cannabis contracts is not just a legal wrangle; it serves as a significant bellwether for the industry as a whole. With a Michigan cultivator, Hello Farms, challenging a troubling court decision that jeopardizes the enforceability of contracts in the cannabis sector, the stakes have never been higher. This historic ruling by the Sixth Circuit Court has cast a shadow over the legality of cannabis contracts nationwide, threatening the very foundation of state-regulated cannabis markets.

Understanding the Ruling: More Than Just a Legal Setback

Hello Farms' CEO Brian Farah passionately argues that the implications of this ruling extend far beyond the $31.8 million jury verdict at stake. “This isn’t just about us; it's a disastrous consequence for all independent operators in the state-legal cannabis industry,” he told Business of Cannabis. The essence of the court's verdict rests on the premise that federal illegality under the Controlled Substances Act nullifies any contracts related to cannabis supply. This sets a precarious precedent for those engaging in legal cannabis commerce, fuelling fears of 'unimaginable instability' as noted by legal experts.

The Ripple Effect: What This Means for Cannabis Entrepreneurs

The decision has led to urgent calls from NORML (National Organization for the Reform of Marijuana Laws) urging for a reconsideration of the ruling. The organization states that accountability in contracts gives consumers and suppliers the confidence needed in a burgeoning industry still grappling with stigma and regulatory challenges. As the court’s decision has thrust cannabis entrepreneurs into uncharted territory, many are left to ponder the sustainability of their business practices if vital contract rights can be tossed aside with a judicial gavel.

Rewritten Contracts: A Proactive Strategy for Farmers and Suppliers

Farah has offered invaluable advice to fellow cannabis suppliers: rethink your contracts to incorporate protective clauses that shield you from this legal vulnerability. “Consider binding arbitration outside the federal court system,” he recommends, “and include rock-solid state-court forum selection clauses to help combat the federal illegality issue.” Such proactive strategies are crucial for those hoping to ensure their businesses remain legally robust in a tumultuous landscape.

A Call for Change: The Road Ahead for Cannabis Law

The future of cannabis legislation remains a mixed bag as entrenched federal limitations hinder progress despite the voice of reformists like NORML. The conversation around the enforceability of cannabis contracts speaks to a larger narrative: how much does federal law stifle state-led progress? The cannabis community appears poised at a pivotal juncture that requires active participation in the legal and political arenas.

As the fight unfolds, we see a familiar theme: advocates raising their voices against outdated regulations. Cannabis legalization isn’t just about enjoying the product; it's about creating a thriving, accountable market that benefits everyone. It’s essential for cannabis professionals to remain engaged in advocacy, supporting efforts to reform not only laws but the cultural perceptions surrounding the industry.

While the immediate circumstances are challenging for Hello Farms, the broader implications present a unique opportunity for collective action across the cannabis community. The call to rethink contracts and engage in reform is more than a strategy; it’s a necessity for future sustainability and growth.

In this uncertain climate, let us rally around the cause, amplifying the voices that advocate for a more just and equitable cannabis marketplace. As an industry, we must push for change that aligns the law with our vibrant, legitimized practices.

Brands

0 Views

0 Comments

Write A Comment

*
*
Please complete the captcha to submit your comment.
Related Posts All Posts

The Prime Leaf Has Been Voted Best Dispensary in Tucson Weekly’s 2026

FOR IMMEDIATE RELEASE October 22, 2026TUCSON, AZ – The Prime Leaf has been voted Best Dispensary in Tucson Weekly’s 2026 Best of Tucson readers’ poll, a recognition made especially meaningful by the community that has supported the locally owned dispensary for years. With two Tucson locations, The Prime Leaf has built its reputation on quality cannabis, friendly knowledgeable staff, and a commitment to keeping its roots firmly planted in the community. From supporting local artists, musicians, and events to giving back through community partnerships. The Prime Leaf has always believed that being a good neighbor is just as important as being a great dispensary. “This award means a lot because it comes directly from the people of Tucson. We’re proud to be locally owned, and even prouder to have a community that continues to support us, ” said Leah Rhey, Marketing Director for The Prime Leaf. As Tucson’s cannabis industry continues to evolve, The Prime Leaf remains committed to the independent, community-focused approach that has defined the business from the beginning. Rooted in Community. Voted Tucson’s Best. The Prime Leaf Midtown: 4420 E. Speedway Blvd., Tucson, AZ University: 1525 N. Park Ave., Tucson, AZ Website: www.theprimeleaf.com

Discover How THCV is Transforming Weight Management with Cannabis

Update Introducing THCV: A Game Changer in Weight Management For the first time in over half a century, UK patients will have access to THCV (Tetrahydrocannabivarin), a cannabinoid gaining attention for its potential to curb appetite. This exciting development comes from the collaboration between Glass Pharms, a UK cannabis cultivator, and Releaf, a pioneering medical cannabis clinic. With the initial supply of 100kg secured for eligible Releaf patients, there is a palpable sense of anticipation surrounding this unique offering. What Makes THCV Unique? While THC, the well-known compound in cannabis, is notorious for enhancing appetite, THCV's effects are intriguingly different. Research indicates that at lower doses, THCV can act as a neutral CB1 antagonist, effectively blocking the receptors associated with hunger. This opens a new avenue in metabolic health, providing a key therapeutic alternative for individuals seeking effective weight management solutions. A Pioneering Step in Medical Cannabis Graham Woodward, Chief Medical Officer at Releaf, emphasizes the importance of offering innovative options to patients who have struggled to find effective weight management strategies. He reflects on how conventional methods do not suit everyone, underscoring THCV's potential role in addressing these unmet needs. “This gives our clinicians another one to consider, case by case,” he adds, highlighting the customizable approach they intend to take with patients. The Clinical Landscape of THCV James Duckenfield, CEO of Glass Pharms, further elaborated on THCV's role in the future of cannabinoid medicine. With its distinct pharmacological properties, including being a partial agonist at higher doses, the cannabinoid encourages a deeper understanding of cannabis as a precise medicine. Duckenfield pointed out the necessity for robust real-world data to determine THCV's efficacy in clinical settings, which will be crucial as more patients gain access to these treatments. Historical Context of Cannabis in the UK Until its prohibition in 1973, cannabis was available in the UK as 'Tincture of Cannabis,' making this new development all the more remarkable. The ban on cannabis produced in the UK effectively severed the connection between patients and this therapeutic option for decades. In 2018, the UK's legalization of medical cannabis sparked hope, yet products available had only offered trace amounts of THCV. Glass Pharms’ cultivation of this compound marks a crucial return of cannabis-derived medicine to the UK market. Looking Ahead: Future Trends and Opportunities The collaborative effort between Glass Pharms and Releaf exemplifies a shift towards a more personalized approach in medical cannabis, paving the way for a greater variety of cannabinoid-based therapies. As research evolves, the potential for other beneficial cannabinoids could emerge, expanding the horizon for treating various metabolic and health conditions. Thus, this partnership not only represents a singular advancement in product availability but also reflects a broader trend as society re-evaluates cannabis's role in health and wellness. Hope is alive, and patients can look forward to exploring cannabinoid therapies that are both clinically valid and beneficial. This new chapter in cannabis medicine in the UK cultivates optimism for the future, encouraging greater exploration and acceptance of cannabinoids in today's healthcare landscape.

Helius Therapeutics and University of Auckland Launch Phase 2 Cannabis Sleep Trial

Update Helius Therapeutics Enters Groundbreaking Cannabis Sleep Study Helius Therapeutics, a trailblazer in New Zealand's medicinal cannabis sector, is embarking on an exciting journey to explore the potential of cannabis as a sleep aid. The company has signed a pivotal supply agreement with the University of Auckland for a Phase 2 clinical trial, which aims to investigate the effectiveness of cannabis-derived medicine for patients struggling with chronic back pain and sleep disturbances. Understanding the CPS Trial's Importance Known as the CPS Trial (Cannabis, Pain, Sleep), this innovative study will unfold over seven months, with participation from prominent institutions including Tauranga Hospital and the University of Otago. Lead investigator Dr. Saad Anis, an experienced pain medicine physician, emphasized the urgent need for credible research, noting that over 20% of New Zealand adults endure chronic non-cancer pain, often accompanied by sleep issues. "Many patients express interest in cannabis-derived medicines, yet definitive evidence is scarce, making it a challenge for healthcare providers to recommend them with confidence," he remarked. The Mechanics of the Trial Participants will engage in a randomized, double-blind, placebo-controlled crossover study, taking the study medicine at bedtime for three months, followed by a placebo for an additional three months. To track the participants’ sleep quality, their sleep patterns will be monitored meticulously using wrist-worn devices. The primary outcome is assessed through the Insomnia Severity Index, complemented by measures of sleep patterns derived from actigraphy. The Significance of High-Quality Evidence The trial, supported by the University of Auckland and an Australian and New Zealand College of Anaesthetists novice investigator grant, aims to produce important data that could reshape the landscape of medicinal cannabis. "This independent study is a crucial step forward for the sector, potentially improving general practice prescriptions and enhancing trust in cannabis therapies," noted Helius Therapeutics CEO Zoë Reece. As the medicinal cannabis sector evolves, effective clinical trials like CPS are viewed as building blocks towards validating these therapies. Growing Demand and Future Prospects As per Health New Zealand's data, medicinal cannabis dispensings have skyrocketed from 4,875 in 2020 to an impressive 389,668 in 2025. This surge highlights the increasing demand for medicinal cannabis as awareness and acceptance grow. Helius Therapeutics is keenly aware of this potential, demonstrating dedication to ensuring reliable and high-quality cannabis products. With over 80 products meeting the rigorous standards of New Zealand's Medicinal Cannabis Scheme, the outlook remains buoyant. What’s Next for the CPS Trial? The results of this pioneering CPS Trial are expected to be published in early 2028, with anticipation high amongst both the medical community and patients alike. Continued research will not only empower practitioners with data but also open avenues for patients to access cannabis therapies that genuinely improve their quality of life. Join the Conversation As the debate around medicinal cannabis evolves, it is crucial for industry stakeholders and patients to stay informed and engaged. Trials like the CPS could redefine how cannabis is perceived and utilized in healthcare, leading to more informed decisions in medical practices. Let's keep sharing these impactful developments!

National Cannabis Newswire
National Cannabis Newswire keeps you informed, empowered, and connected to the Cannabis community.

COMPANY

  • Privacy Policy
  • Terms of Use
  • Advertise
  • Contact Us
  • Menu 5
  • Menu 6

480.878.1919

AVAILABLE FROM 8AM - 5PM PST

Contact

11504 W Piccadilly Rd,
Avondale, AZ 85392,

ABOUT US

Your source for breaking cannabis industry news, expert insights, and nationwide updates—National Cannabis Newswire keeps you informed, empowered, and connected.

© 2026 CompanyName All Rights Reserved. Address . Contact Us . Terms of Service . Privacy Policy

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*